石藥集團(01093.HK)擬收購銘康生物股份權益
格隆匯2月8日丨石藥集團(01093.HK)發佈公吿,集團已完成向獨立第三方收購於中國成立的有限合夥企業珠海至凡企業管理諮詢中心(有限合夥)(“珠海至凡”)的100%權益。
根據披露,珠海至凡目前持有於中國成立的有限公司廣州銘康生物工程有限公司(“銘康生物”)的註冊資本人民幣9445.29萬元(其中人民幣3286.65萬元尚未繳付),佔銘康生物於該公吿日期的註冊資本總額約51%。根據相關協議,集團將透過珠海至凡向銘康生物注資人民幣1.54億元(其中人民幣3286.65萬元將用作繳足尚未繳付的註冊資本,餘下人民幣1.22億元將用作資本公積金)。珠海至凡的主要業務為投資銘康生物。
銘康生物自主研發的銘復樂(注射用重組人TNK組織型纖溶酶原激活劑)為具有知識產權的第三代特異性溶栓藥,於2015年在國內上市,用於發病6小時以內的急性心肌梗死患者溶栓的治療;其用於腦梗死溶栓的適應症於2017年獲得臨牀試驗批件,並於2021年開展Ⅲ期臨牀試驗(TRACE II)。截至2022年1月28日,已啟動61家研究中心,入組患者1,362例。
2000年成立的銘康生物是一間從事生物藥研發、生產和銷售的生物技術公司。銘康生物的技術團隊在生物新藥的研發、生產和質量管理方面經驗豐富,尤其在動物細胞培養和蛋白分離技術方面有着深厚積累,並建有國際一流的GMP認證生產廠房和哺乳動物細胞連續培養工業化生產線。公司認為該產品具有很好的商業潛力,收購事項將進一步加強集團的產品管線,並提供新的增長動力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.